A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...